Affinage

KLF13

Krueppel-like factor 13 · UniProt Q9Y2Y9

Length
288 aa
Mass
31.2 kDa
Annotated
2026-04-28
62 papers in source corpus 30 papers cited in narrative 30 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

KLF13 is a Krüppel-like zinc-finger transcription factor that functions as both a transcriptional activator and repressor in a promoter- and cell-type-dependent manner, orchestrating gene programs in immune cell development, cardiac morphogenesis, lipid metabolism, neuronal maturation, and tumor suppression. KLF13 represses target genes by recruiting a SIN3A–HDAC1 co-repressor complex and by competing with Sp1 for GC-rich DNA elements, while it activates transcription through synergistic interactions with GATA-4, TBX5, c-Maf, and p300/PCAF-mediated acetylation (PMID:11477107, PMID:17053787, PMID:28164238, PMID:24821970, PMID:41438085). KLF13 protein abundance is tightly regulated post-translationally by GSK3β-mediated phosphorylation triggering FBXW7-dependent proteasomal degradation, by FBXW5-mediated ubiquitination, and translationally through a 5′-UTR mechanism involving eIF4E and MAPK signaling (PMID:22797700, PMID:40696794, PMID:12093895). In vivo, KLF13 deficiency causes atrial septal defects and hypotrabeculation in Xenopus, exacerbates cardiac septal defects when combined with Tbx5 haploinsufficiency in mice, impairs T and B cell development, reduces IL-4 and Th2 cytokine production, and disrupts iNKT cell maintenance (PMID:17053787, PMID:28164238, PMID:18604172, PMID:21482696, PMID:24821970).

Mechanistic history

Synthesis pass · year-by-year structured walk · 15 steps
  1. 2001 High

    Establishing that KLF13 is a direct transcriptional repressor resolved how this Krüppel-like factor silences GC-rich promoters: through an N-terminal repressor domain that recruits the mSin3A–HDAC1 co-repressor complex and competition with Sp1 for DNA binding.

    Evidence Co-IP, GAL4 fusion/reporter assays, and gel shift in CHO cells

    PMID:11477107

    Open questions at the time
    • Whether mSin3A/HDAC1 recruitment is required at all endogenous KLF13 target promoters
    • No genome-wide target identification at this stage
  2. 2002 High

    Mapping of separable activation and repression domains, dual nuclear localization signals, and the critical RANTES promoter binding site established KLF13 as a modular transcription factor with context-dependent output, while the concurrent discovery of 5′-UTR-mediated translational control via eIF4E and MAPK signaling revealed a major post-transcriptional layer governing KLF13 protein levels.

    Evidence GAL4 deletion/mutagenesis, GFP-NLS mapping, gel shift, reporter assays; eIF4E overexpression, Mnk1/MAPK inhibitors, qPCR/protein analysis in T cells

    PMID:12050170 PMID:12093895

    Open questions at the time
    • Relative contribution of translational vs. post-translational control in different cell types
    • Identity of RNA-binding proteins mediating 5′-UTR regulation
  3. 2003 High

    Demonstrating that CBP and PCAF acetylate KLF13's zinc finger domain with opposing effects on DNA binding established that post-translational acetylation serves as a molecular switch modulating KLF13 transcriptional activity.

    Evidence In vitro acetylation assays, gel shifts, site-directed mutagenesis, co-activator co-expression reporter assays

    PMID:12758070

    Open questions at the time
    • In vivo acetylation dynamics at endogenous targets
    • Whether acetylation status differs between activation and repression contexts
  4. 2005 High

    ChIP-based demonstration that KLF13 binds the LDLR promoter in vivo, repressing it in a manner antagonized by Sp1/SREBP and upregulated by oxysterols, placed KLF13 within cholesterol homeostasis pathways and validated the Sp1-competition model at an endogenous locus.

    Evidence ChIP, EMSA, RNAi, reporter assays, HDAC inhibitor treatment

    PMID:16303770

    Open questions at the time
    • Systemic lipid phenotype in KLF13 knockout animals
    • Interplay with other KLFs on lipid-related promoters
  5. 2006 High

    Discovery that KLF13 physically interacts with GATA-4 and synergistically activates cardiac gene expression, and that KLF13 morpholino knockdown in Xenopus causes atrial septal defects, established KLF13 as a cardiac transcription factor essential for heart morphogenesis.

    Evidence Co-IP, reporter synergy assays, Xenopus morpholino knockdown, in situ hybridization

    PMID:17053787

    Open questions at the time
    • Cardiac phenotype in mammalian KLF13 knockouts not yet reported at this time
    • Whether KLF13 mutations cause human congenital heart disease
  6. 2008 High

    KLF13 knockout mice revealed that KLF13 is required for normal T cell maturation (DP-to-SP transition), peripheral T cell activation, and B cell development, establishing broad immune system functions beyond the previously known RANTES regulation.

    Evidence KLF13 knockout mice, flow cytometry, surface marker analysis

    PMID:18604172

    Open questions at the time
    • Direct transcriptional targets mediating each immune checkpoint defect
    • Redundancy with other KLF family members in immune cells
  7. 2010 High

    Identification of miR-125a as a direct negative regulator of KLF13 mRNA via its 3′-UTR added a microRNA-mediated layer to KLF13 regulation and linked dysregulated KLF13/RANTES to autoimmune pathology in SLE T cells.

    Evidence Luciferase reporter, gain/loss-of-function miRNA transfection, ELISA in activated T cells

    PMID:20589685

    Open questions at the time
    • Whether other miRNAs cooperatively regulate KLF13
    • In vivo confirmation of miR-125a–KLF13 axis in autoimmune models
  8. 2011 High

    Demonstrating that KLF13 maintains IL-4-producing iNKT cells in BALB/c mice, and that KLF13 deficiency phenocopies IL-4 neutralization for thymic memory CD8+ T cell generation, positioned KLF13 upstream of IL-4 in a strain-specific innate-adaptive immune circuit.

    Evidence KLF13 KO on BALB/c background, IL-4 neutralization and supplementation, flow cytometry

    PMID:21482696

    Open questions at the time
    • Whether KLF13 directly drives IL-4 transcription or acts indirectly through iNKT cell survival
  9. 2012 High

    Identification of GSK3β-mediated phosphorylation followed by Fbw7γ-dependent ubiquitination as the mechanism controlling KLF13 protein degradation in resting human T cells revealed the primary post-translational destruction pathway and explained species-specific differences in RANTES kinetics.

    Evidence Proteasomal/lysosomal inhibitors, GSK3β and Fbw7γ siRNA, western blot in human vs. murine T cells

    PMID:22797700

    Open questions at the time
    • Precise phosphodegron residues on KLF13
    • Whether Fbw7α/β isoforms also target KLF13 in non-lymphoid tissues
  10. 2014 High

    ChIP-confirmed direct binding of KLF13 to IL-4 promoter regions, combined with synergy with c-Maf, resolved the earlier question of whether KLF13 directly activates IL-4 transcription in CD4+ T cells.

    Evidence KLF13 KO mice, ChIP, reporter/synergy assays, gene expression analysis

    PMID:24821970

    Open questions at the time
    • Whether KLF13 regulates IL-4 in iNKT cells through the same mechanism as in CD4+ T cells
    • Genome-wide KLF13 binding landscape in T cells
  11. 2017 High

    Physical interaction of KLF13 with TBX5 and genetic epistasis in double-heterozygous mice linked KLF13 to Holt-Oram syndrome biology and demonstrated that KLF13 haploinsufficiency sensitizes to cardiac septal defects in the Tbx5 heterozygous background.

    Evidence Co-IP, reporter synergy assays, disease-causing TBX5 mutagenesis, Klf13+/−;Tbx5+/− double-heterozygous mice

    PMID:28164238

    Open questions at the time
    • Whether human KLF13 mutations cause congenital heart disease independently
    • Structural basis of the KLF13–TBX5 interaction
  12. 2020 Medium

    ChIP-confirmed direct repression of HMGCS1 by KLF13 established a cholesterol biosynthesis–dependent tumor-suppressive mechanism in colorectal cancer, expanding the functional repertoire from LDLR regulation to mevalonate pathway control.

    Evidence ChIP-qPCR, luciferase assay, siRNA knockdown, overexpression rescue, xenograft

    PMID:32523679

    Open questions at the time
    • Whether KLF13 coordinately represses multiple mevalonate pathway genes
    • Confirmation in independent cohorts or labs
  13. 2023 High

    Demonstration that KLF13 recruits SIN3A–HDAC1 to TGF-β target gene promoters as a negative feedback brake on fibrosis, and that persistent TGF-β signaling degrades KLF13 via FBXW7, unified the repressor complex and ubiquitination mechanisms into a coherent anti-fibrotic circuit.

    Evidence KLF13 global KO mice, AAV-mediated rescue, Co-IP for SIN3A/HDAC1, ChIP, FBXW7 interaction studies

    PMID:37029927

    Open questions at the time
    • Tissue-specific fibrotic phenotypes in KLF13 KO mice beyond those tested
    • Whether KLF13 loss contributes to human fibrotic diseases
  14. 2024 Medium

    Discovery that KLF13 directly represses Dll4 transcription to inhibit the Dll4-Notch2 axis in muscle, and that dexamethasone degrades KLF13 via FBXW7 while also suppressing MYOD1-driven KLF13 transcription, revealed KLF13 as a protective factor against glucocorticoid-induced muscle atrophy.

    Evidence KLF13 KO and overexpression in cell and mouse models, luciferase reporter, MYOD1 interaction analysis

    PMID:38973459

    Open questions at the time
    • Whether FBXW7 targets the same phosphodegron as in T cells
    • In vivo rescue of dexamethasone atrophy by KLF13 overexpression not independently confirmed
  15. 2025 Medium

    Multiple concurrent studies identified new direct KLF13 targets (GPX4, CES2, TROAP, SH2B1, GPIHBP1, HTRA1) across cancer types, and identified FBXW5 as an additional E3 ligase for KLF13, broadening the target repertoire to ferroptosis, drug metabolism, EMT, glycolysis, and lipid metabolism while expanding the ubiquitin ligase landscape.

    Evidence ChIP/ChIP-seq, luciferase assays, Co-IP for FBXW5, functional rescue experiments, xenograft models across lung, gastric, esophageal, and breast cancer lines

    PMID:40450000 PMID:40555914 PMID:40597044 PMID:40696794 PMID:41410190 PMID:41438085

    Open questions at the time
    • Most findings from single labs; independent replication needed
    • Genome-wide ChIP-seq in normal tissues to distinguish direct from cancer-context targets
    • Structural basis for KLF13 recognition by FBXW5 vs. FBXW7

Open questions

Synthesis pass · forward-looking unresolved questions
  • A unified genome-wide map of KLF13 binding across tissues, the structural basis for promoter-context-dependent activation versus repression switching, and whether human KLF13 loss-of-function variants cause congenital heart disease or immunodeficiency remain unresolved.
  • No crystal or cryo-EM structure of KLF13 alone or in complex
  • No human genetics study identifying causative KLF13 mutations in disease
  • No systematic comparison of KLF13 vs. KLF9 target overlap genome-wide

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 15 GO:0003677 DNA binding 8
Localization
GO:0005634 nucleus 3
Pathway
R-HSA-168256 Immune System 4 R-HSA-392499 Metabolism of proteins 4 R-HSA-1266738 Developmental Biology 2 R-HSA-162582 Signal Transduction 2
Partners
CBPFBXW5FBXW7GATA4HDAC1PGC1ASIN3ATBX5
Complex memberships
SIN3A–HDAC1 co-repressor complex

Evidence

Reading pass · 30 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2001 KLF13 (BTEB3) contains a direct repressor domain in its N-terminus that interacts with co-repressor mSin3A and histone deacetylase HDAC-1, and mediates repression also by competing with Sp1 for binding to GC-rich BTE DNA elements. Immunoprecipitation, GAL4 fusion assays, gel shift assays, reporter assays in CHO cells The Journal of biological chemistry High 11477107
2002 KLF13 (RFLAT-1) has distinct N-terminal transcriptional activation (aa 1-35) and repression (aa 67-168) domains; contains two independent nuclear localization signals (one upstream of and one within the zinc fingers); binds the critical CTCCC sequence on the RANTES promoter; and synergizes with NF-κB for RANTES transcription. GAL4 fusion system, deletion analysis, site-directed mutagenesis, GFP fusion NLS mapping, gel shift/mutational analysis, reporter assays The Journal of biological chemistry High 12050170
2002 KLF13 (RFLAT-1) protein expression is translationally regulated through its 5'-UTR in a cell-type-specific manner via cap-dependent translation involving eIF4E and its kinase Mnk1, downstream of ERK-1/2 and p38 MAP kinases. Overexpression of eIF4E, Mnk1 inhibition, kinase pathway inhibitors, quantitative PCR and protein analysis The Journal of clinical investigation High 12093895
2003 CBP and PCAF co-activators acetylate KLF13 at specific lysine residues in its zinc finger domain; CBP acetylation disrupts KLF13 DNA binding, while PCAF blocks CBP-mediated acetylation to prevent this disruption, and CBP acetylation of KLF13 prevents PCAF stimulation of KLF13 DNA binding—demonstrating antagonistic and synergistic functional interplay between the two acetyltransferases. In vitro acetylation assays, gel shift assays, site-directed mutagenesis, co-activator co-expression reporter assays Journal of molecular biology High 12758070
2003 KLF13 (BTEB3) binds to TGGG repeat motifs in the SM22α promoter and activates or inhibits reporter gene expression depending on which TGGG box it occupies; only one of three boxes is required for BTEB3-dependent activation in P19 cells; KLF13 activates the SM22α promoter in vascular smooth muscle cells (VSMCs) and is expressed in VSMCs in vitro with modulated expression after injury in vivo. Recombinant protein binding assays, mutation analysis, transient transfection reporter assays in P19 and VSMC cells The Biochemical journal Medium 12848620
2005 KLF13 represses the low density lipoprotein receptor (LDLR) promoter by binding proximal LDLR DNA sequences in vivo (confirmed by ChIP) in a DNA context-selective manner; this repression is antagonized by Sp1 and SREBP, and KLF13 binding is upregulated by oxysterols. RNA interference, EMSA, ChIP, reporter assays, deletion and site-directed mutagenesis, HDAC inhibitor treatment The Journal of biological chemistry High 16303770
2006 KLF13 binds conserved regulatory elements on cardiac promoters, activates cardiac transcription, and physically and functionally interacts with GATA-4 to synergistically activate cardiac gene expression; knockdown of KLF13 in Xenopus embryos causes atrial septal defects and hypotrabeculation similar to GATA-4 hypomorphs. Xenopus knockdown (morpholino), co-immunoprecipitation, reporter assays, in situ hybridization, promoter binding assays The EMBO journal High 17053787
2008 KLF13 deficiency in mice causes accumulation of DP thymocytes, reduction of CD4+ SP cells, altered surface expression of CD3, CD8, CD5, and HSA on DP cells consistent with TCR signaling defects, impaired peripheral T cell activation, a partial block at the CD43+ to CD43− pre-B cell transition, and increased CD21/CD23 expression on peripheral B cells. KLF13 knockout mice, flow cytometry, cell surface marker analysis Cell cycle (Georgetown, Tex.) High 18604172
2010 miR-125a directly targets the 3'-UTR of KLF13 mRNA (confirmed by luciferase reporter), negatively regulates KLF13 protein expression in a dose-dependent manner, and thereby suppresses RANTES expression in activated T cells. Luciferase reporter assay, gain- and loss-of-function miRNA transfection, qPCR, ELISA Arthritis and rheumatism High 20589685
2010 KLF13 participates in uterine stromal cell differentiation through cross-regulation with BMP2 and KLF9: KLF13 knockdown attenuates BMP2 expression and abrogates BMP2-mediated inhibition of KLF9, while KLF13 expression is positively associated with BMP2 and inversely with KLF9. siRNA knockdown in human endometrial stromal cells (HESCs), recombinant BMP2 treatment, KLF9 null mice, qPCR Endocrinology Medium 20410205
2011 KLF13 is required in BALB/c mice for maintenance of IL-4-generating invariant NKT (iNKT) cells; KLF13-deficient BALB/c mice have iNKT cell numbers comparable to C57BL/6 mice and extremely low levels of thymic memory-like CD8+ T cells, demonstrating that KLF13 sustains iNKT cells that produce IL-4 sufficient to drive thymic memory-like CD8+ T cell generation. KLF13 knockout mice (BALB/c background), flow cytometry, IL-4 neutralization, IL-4 supplementation The Journal of experimental medicine High 21482696
2012 KLF13 protein is degraded in resting human T lymphocytes via GSK3β-mediated phosphorylation that triggers ubiquitination by the E3 ligase Fbw7γ; proteasomal or lysosomal inhibition stabilizes KLF13 and increases RANTES expression. This mechanism is absent in murine T cells due to lack of Fbw7γ. Proteasomal/lysosomal inhibitor treatment, GSK3β and Fbw7γ siRNA knockdown, protein analysis by western blot Blood High 22797700
2014 KLF13 directly binds IL-4 promoter regions and synergizes with the transcription factor c-Maf to positively regulate IL-4 expression in CD4+ T cells; KLF13-deficient mice show reduced IL-4 and Th2 cytokine gene expression without changes in GATA3 or c-Maf levels. KLF13 knockout mice, gene expression analysis, ChIP (promoter binding), reporter/synergy assays Journal of immunology High 24821970
2015 KLF13 promotes porcine adipocyte differentiation by directly binding to a KLF13-binding site within the −593/−577 region of the porcine PPARγ proximal promoter and transactivating PPARγ expression; siRNA knockdown of KLF13 attenuates porcine adipocyte differentiation. siRNA knockdown, KLF13 overexpression, promoter deletion and mutation analysis, luciferase reporter assay Cell & bioscience Medium 26085920
2016 KLF13 is upregulated in HPV-positive keratinocytes via HPV E7 protein suppression of ubiquitin ligase FBW7; KLF13 is required for HPV productive life cycle by supporting STAT5 expression, which activates the ATM DNA damage pathway and IL-8 chemokine; neutralization of IL-8 diminishes viral genome amplification. shRNA knockdown, qPCR, western blot, viral genome amplification assays, IL-8 neutralization Oncogene Medium 27041562
2017 KLF13 physically interacts with TBX5 via TBX5's T-domain and synergistically activates transcription of cardiac genes; disease-causing TBX5 mutations in the T-domain reduce KLF13 interaction; loss of one Klf13 allele in Tbx5 heterozygous mice significantly increases penetrance of cardiac septal defects. Co-immunoprecipitation, reporter synergy assays, genetic epistasis in double-heterozygous mice, mutagenesis Human molecular genetics High 28164238
2019 The antibiotic clofoctol upregulates KLF13 expression through its targeted binding protein UNR (Upstream of N-ras), an RNA-binding protein; elevated KLF13 acts as a tumor suppressor to inhibit glioma stem cell proliferation and induce apoptosis. High-throughput drug screening, target binding protein identification, downstream gene analysis, patient-derived xenografts, colony formation and apoptosis assays The Journal of clinical investigation Medium 31112526
2020 KLF13 transcriptionally inhibits HMGCS1 promoter activity (confirmed by ChIP-qPCR and luciferase assay), reducing cholesterol biosynthesis in colorectal cancer cells; KLF13 knockdown or HMGCS1 overexpression rescues proliferation, establishing KLF13→HMGCS1→cholesterol biosynthesis as the tumor-suppressive mechanism. ChIP-qPCR, luciferase reporter assay, siRNA knockdown, overexpression, CCK-8, colony formation, cell cycle analysis, xenograft Cell & bioscience Medium 32523679
2023 KLF13 recruits a repressor complex comprising SIN3A and HDAC1 to TGF-β target gene promoters, limiting their profibrotic induction; TGF-β transiently induces KLF13 as a negative feedback loop, but persistent TGF-β signaling reduces KLF13 through FBXW7-mediated ubiquitination degradation and HDAC-dependent transcriptional inhibition. KLF13 global knockout mice, AAV-mediated overexpression, ChIP, Co-IP for SIN3A/HDAC1 complex, reporter assays, FBXW7 interaction studies Cell reports High 37029927
2023 KLF13 directly regulates expression of JAK/STAT pathway genes (Jak1, Jak2, Jak3, Socs1) by binding their proximal promoters; KLF13 differentially modulates GH-induced JAK/STAT signaling by decreasing the STAT3 branch while enhancing STAT5 activity; GH treatment increases nuclear KLF13 content and Klf13 mRNA. ChIP, KLF13-deficient HT22 neuronal cells, qPCR, reporter assays, GH stimulation experiments International journal of molecular sciences Medium 37446365
2024 KLF13 directly binds the SM22α promoter to suppress its expression, promoting vascular smooth muscle cell (VSMC) phenotypic dedifferentiation; KLF13 knockdown ameliorates intimal hyperplasia after carotid injury, at least partly through inactivation of p-AKT signaling. Bioinformatics, atherosclerotic plaque analysis (human and ApoE−/− mice), siRNA knockdown, ChIP, reporter assay, carotid injury mouse model Journal of cellular physiology Medium 38634445
2024 KLF13 represses Dll4 transcription (confirmed by luciferase reporter assay), inhibiting the Dll4-Notch2 axis and thereby preventing muscle atrophy; dexamethasone inhibits KLF13 expression by suppressing MYOD1-mediated KLF13 transcriptional activation and promoting FBXW7-mediated KLF13 ubiquitination. Transcriptome analysis, luciferase reporter assays, KLF13 KO and overexpression in cell and mouse models, MYOD1 interaction analysis Journal of cachexia, sarcopenia and muscle Medium 38973459
2024 KLF13 physically interacts with PGC-1α (confirmed by Co-IP) to regulate mitochondrial quality control in alveolar epithelial cells; KLF13 overexpression reduces LPS-induced inflammation and apoptosis, and PGC-1α knockdown reverses these protective effects. Co-immunoprecipitation, KLF13 overexpression, PGC-1α siRNA, MitoSOX staining, JC-1 staining, western blot Journal of interferon & cytokine research Medium 38949897
2025 KLF13 directly binds the GPX4 promoter (by ChIP and dual-luciferase assay) to inhibit GPX4 transcription, thereby promoting ferroptosis in lung adenocarcinoma; overexpression of GPX4 reverses KLF13-induced ferroptosis sensitization. ChIP assay, dual-luciferase reporter assay, stable overexpression/knockdown cell lines, ROS detection, cytotoxicity assays, xenograft model BMC biology Medium 40597044
2025 KLF13 directly binds the CES2 promoter to transcriptionally activate CES2 expression; this transcriptional activation is dependent on acetylation of KLF13 by the co-activator p300, as shown by mutagenesis and p300 inhibition; the KLF13-CES2 axis controls cellular sensitivity to irinotecan in gastric cancer. ChIP, dual-luciferase reporter assay, site-directed mutagenesis of acetylation sites, p300 inhibition, irinotecan sensitivity assays iScience Medium 41438085
2025 FBXW5 promotes ubiquitin-mediated degradation of KLF13 (confirmed by CoIP); reduced KLF13 releases transcriptional repression of TROAP, facilitating EMT in lung adenocarcinoma; KLF13 directly represses TROAP transcription as shown by ChIP and luciferase assays. Co-immunoprecipitation, ChIP, dual luciferase reporter assay, siRNA/overexpression, western blot, xenograft model Molecular carcinogenesis Medium 40696794
2025 KLF13 transcriptionally represses SH2B1 expression by binding its promoter, which abolishes the SH2B1-IRS1 protein interaction (confirmed by Co-IP and GST pulldown), thereby repressing PI3K/AKT-mediated glycolysis in NSCLC cells. ChIP, dual-luciferase reporter assay, EMSA, Co-IP, GST pulldown, glycolysis assays (OCR, ECAR), xenograft model Clinical and translational medicine Medium 41410190
2025 KLF13 directly promotes GPIHBP1 transcription (confirmed by luciferase and ChIP assays), regulating triacylglyceride and free fatty acid metabolism, and promoting esophageal cancer progression through this axis. RNA-seq, ChIP-seq, ChIP-qPCR, luciferase assay, shRNA and overexpression recovery assays, xenograft model Cell death & disease Medium 40450000
2025 KLF13 promotes HTRA1 transcription (by ChIP-seq and luciferase assays) and activates the Hedgehog signaling pathway to drive breast cancer aggressiveness and immune evasion; HTRA1 overexpression rescues the anti-tumor effects of KLF13 silencing. ChIP-seq, luciferase assay, RNA-seq, siRNA knockdown, overexpression, in vivo xenograft Breast cancer (Tokyo, Japan) Medium 40555914
2025 KLF13 acts as a transcriptional repressor of KLF target genes in maturing neocortical neurons, functioning as part of a transcriptional 'switch' from KLF activators (Klf6, Klf7) to repressors (Klf9, Klf13) that represses shared cytoskeletal targets including Tubb2b and Dpysl3 during postnatal neuronal maturation. Multiplexed CRISPRi knockdown in mouse neocortical neurons, chromatin accessibility analysis, gene expression profiling bioRxivpreprint Medium bio_10.1101_2025.02.07.636951

Source papers

Stage 0 corpus · 62 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2010 MicroRNA-125a contributes to elevated inflammatory chemokine RANTES levels via targeting KLF13 in systemic lupus erythematosus. Arthritis and rheumatism 182 20589685
2017 A carvedilol-responsive microRNA, miR-125b-5p protects the heart from acute myocardial infarction by repressing pro-apoptotic bak1 and klf13 in cardiomyocytes. Journal of molecular and cellular cardiology 76 29122578
2001 The Sp1-like protein BTEB3 inhibits transcription via the basic transcription element box by interacting with mSin3A and HDAC-1 co-repressors and competing with Sp1. The Journal of biological chemistry 74 11477107
2006 The Kruppel-like transcription factor KLF13 is a novel regulator of heart development. The EMBO journal 71 17053787
2000 FKLF-2: a novel Krüppel-like transcriptional factor that activates globin and other erythroid lineage genes. Blood 69 10828046
2000 Identification of KLF13 and KLF14 (SP6), novel members of the SP/XKLF transcription factor family. Genomics 66 11087666
2011 KLF13 sustains thymic memory-like CD8(+) T cells in BALB/c mice by regulating IL-4-generating invariant natural killer T cells. The Journal of experimental medicine 63 21482696
2002 A translational rheostat for RFLAT-1 regulates RANTES expression in T lymphocytes. The Journal of clinical investigation 57 12093895
2002 Functional domains and DNA-binding sequences of RFLAT-1/KLF13, a Krüppel-like transcription factor of activated T lymphocytes. The Journal of biological chemistry 49 12050170
2019 The antibiotic clofoctol suppresses glioma stem cell proliferation by activating KLF13. The Journal of clinical investigation 48 31112526
2015 KLF13 promotes porcine adipocyte differentiation through PPARγ activation. Cell & bioscience 48 26085920
2010 Overexpression of KLF13 and FGFR3 in oral cancer cells. Cytogenetic and genome research 46 20539070
2011 Homozygous deletion of chromosome 15q13.3 including CHRNA7 causes severe mental retardation, seizures, muscular hypotonia, and the loss of KLF13 and TRPM1 potentially cause macrocytosis and congenital retinal dysfunction in siblings. European journal of medical genetics 43 21596161
2020 KLF13 suppresses the proliferation and growth of colorectal cancer cells through transcriptionally inhibiting HMGCS1-mediated cholesterol biosynthesis. Cell & bioscience 42 32523679
2010 Functional differentiation of uterine stromal cells involves cross-regulation between bone morphogenetic protein 2 and Kruppel-like factor (KLF) family members KLF9 and KLF13. Endocrinology 38 20410205
2003 Functional interplay between CBP and PCAF in acetylation and regulation of transcription factor KLF13 activity. Journal of molecular biology 37 12758070
2000 Mouse BTEB3, a new member of the basic transcription element binding protein (BTEB) family, activates expression from GC-rich minimal promoter regions. The Biochemical journal 34 10642511
2016 KLF13 regulates the differentiation-dependent human papillomavirus life cycle in keratinocytes through STAT5 and IL-8. Oncogene 33 27041562
2022 UC-BSCs Exosomes Regulate Th17/Treg Balance in Patients with Systemic Lupus Erythematosus via miR-19b/KLF13. Cells 32 36552891
2018 Transcription factor KLF13 inhibits AKT activation and suppresses the growth of prostate carcinoma cells. Cancer biomarkers : section A of Disease markers 31 29843216
2001 Expression of Klf9 and Klf13 in mouse development. Mechanisms of development 30 11335124
2008 KLF13 influences multiple stages of both B and T cell development. Cell cycle (Georgetown, Tex.) 28 18604172
2018 MiR-147b inhibits cell viability and promotes apoptosis of rat H9c2 cardiomyocytes via down-regulating KLF13 expression. Acta biochimica et biophysica Sinica 24 29377979
2005 A novel functional interaction between the Sp1-like protein KLF13 and SREBP-Sp1 activation complex underlies regulation of low density lipoprotein receptor promoter function. The Journal of biological chemistry 23 16303770
2017 KLF13 is a genetic modifier of the Holt-Oram syndrome gene TBX5. Human molecular genetics 22 28164238
2014 KLF13 cooperates with c-Maf to regulate IL-4 expression in CD4+ T cells. Journal of immunology (Baltimore, Md. : 1950) 20 24821970
2023 Sp1-like protein KLF13 acts as a negative feedback regulator of TGF-β signaling and fibrosis. Cell reports 19 37029927
2017 Obesity-related CpG Methylation (cg07814318) of Kruppel-like Factor-13 (KLF13) Gene with Childhood Obesity and its cis-Methylation Quantitative Loci. Scientific reports 19 28508896
2022 A novel KLF13 mutation underlying congenital patent ductus arteriosus and ventricular septal defect, as well as bicuspid aortic valve. Experimental and therapeutic medicine 16 35369534
2012 Fbw7γ-mediated degradation of KLF13 prevents RANTES expression in resting human but not murine T lymphocytes. Blood 16 22797700
2022 Low expression of PEBP1P2 promotes metastasis of clear cell renal cell carcinoma by post-transcriptional regulation of PEBP1 and KLF13 mRNA. Experimental hematology & oncology 15 36348434
2022 KLF13 overexpression protects sepsis-induced myocardial injury and LPS-induced inflammation and apoptosis. International journal of experimental pathology 15 36583453
2019 Downregulation of KLF13 through DNMT1-mediated hypermethylation promotes glioma cell proliferation and invasion. OncoTargets and therapy 15 30863117
2022 KLF13 Loss-of-Function Mutations Underlying Familial Dilated Cardiomyopathy. Journal of the American Heart Association 14 36346048
2022 The inhibitory effect of LINC00261 upregulation on the pancreatic cancer EMT process is mediated by KLF13 via the mTOR signaling pathway. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 13 35066757
2020 KLF13 loss-of-function variation contributes to familial congenital heart defects. European review for medical and pharmacological sciences 13 33215447
2020 Long noncoding RNA FTX ameliorates hydrogen peroxide-induced cardiomyocyte injury by regulating the miR-150/KLF13 axis. Open life sciences 13 33817286
2020 Downregulation of miR-96 suppresses the profibrogenic functions of cardiac fibroblasts induced by angiotensin II and attenuates atrial fibrosis by upregulating KLF13. Human cell 12 32034721
2024 miR-135b Aggravates Fusobacterium nucleatum-Induced Cisplatin Resistance in Colorectal Cancer by Targeting KLF13. Journal of microbiology (Seoul, Korea) 11 38402337
2003 Selective modulation of the SM22alpha promoter by the binding of BTEB3 (basal transcription element-binding protein 3) to TGGG repeats. The Biochemical journal 11 12848620
2020 Identification and analysis of KLF13 variants in patients with congenital heart disease. BMC medical genetics 10 32293321
2020 The potential role of Krüppel-like factor 13 (Aj-klf13) in the intestine regeneration of sea cucumber Apostichopus japonicus. Gene 8 32007582
2005 Transcriptional regulation of FKLF-2 (KLF13) gene in erythroid cells. Biochimica et biophysica acta 8 15716005
2024 Bioinformatic Evaluation of KLF13 Genetic Variant: Implications for Neurodevelopmental and Psychiatric Symptoms. Genes 6 39202416
2020 Breakpoint Mapping of Symptomatic Balanced Translocations Links the EPHA6, KLF13 and UBR3 Genes to Novel Disease Phenotype. Journal of clinical medicine 6 32344861
2023 KLF13 Regulates the Activity of the GH-Induced JAK/STAT Signaling by Targeting Genes Involved in the Pathway. International journal of molecular sciences 5 37446365
2017 A DNA methylation site within the KLF13 gene is associated with orexigenic processes based on neural responses and ghrelin levels. International journal of obesity (2005) 5 28194012
2024 KLF13 promotes VSMCs phenotypic dedifferentiation by directly binding to the SM22α promoter. Journal of cellular physiology 4 38634445
2025 KLF13 promotes esophageal cancer progression and regulates triacylglyceride and free fatty acid metabolism through GPIHBP1. Cell death & disease 3 40450000
2024 KLF13 promotes SLE pathogenesis by modifying chromatin accessibility of key proinflammatory cytokine genes. Communications biology 3 39506084
2021 KLF13 induces apoptotic cell clearance in Penaeus vannamei as an essential part of shrimp innate immune response to pathogens. Developmental and comparative immunology 3 34450131
2025 KLF13 promotes ferroptosis and chemosensitivity in lung adenocarcinoma. BMC biology 2 40597044
2024 KLF13 restrains Dll4-muscular Notch2 axis to improve the muscle atrophy. Journal of cachexia, sarcopenia and muscle 2 38973459
2025 CircZMYM2 Alleviates TGF-β1-Induced Proliferation, Migration and Activation of Fibroblasts via Targeting miR-199b-5p/KLF13 Axis. Applied biochemistry and biotechnology 1 39808406
2025 KLF13 promotes breast cancer progression through the HTRA1 and the Hedgehog signaling pathway. Breast cancer (Tokyo, Japan) 1 40555914
2025 FBXW5 Promotes Epithelial-Mesenchymal Transition in Lung Adenocarcinoma Through the KLF13/TROAP Signaling Pathway. Molecular carcinogenesis 1 40696794
2025 Exosomal miR-3126-5p derived from cancer-associated fibroblasts facilitates glycolysis to accelerate NSCLC progression by targeting KLF13 to activate the SH2B1/IRS1 axis. Clinical and translational medicine 1 41410190
2024 KLF13 Attenuates Lipopolysaccharide-Induced Alveolar Epithelial Cell Damage by Regulating Mitochondrial Quality Control via Binding PGC-1α. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 1 38949897
2025 Ascending E2F7a/b ratio facilitates KLF13 transcription in hepatocellular carcinoma and correlates with the abundance of binuclear hepatocytes (ABH) modulation for short-term recurrence. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 0 40116212
2025 A new KLF13 loss-of-function mutation responsible for sporadic dilated cardiomyopathy. Molecular biology reports 0 41201692
2025 Exosomal lncRNA XR_001793654.1 in human cardiac explant-derived alleviates atrial fibrillation via abolishing the miR-107-3p-mediated KLF13 inhibition. Frontiers in cell and developmental biology 0 41278196
2025 KLF13-mediated CES2 upregulation via p300-dependent acetylation sensitizes gastric cancer cells to irinotecan. iScience 0 41438085